Clarendon portfolio company Fusion Antibodies the pharmaceutical contract research company have said full-year revenues rose almost 80 per cent in the year to the end of March. The company said revenues rose to £3.9 million (€4.3 million), up from £2.2 million in the same period a year earlier. The increase has been well flagged by […]
Fusion Antibodies sees annual revenues rise almost 80% Read More »
Clarendon portfolio company Liopa the Belfast-based start-up, a spin-out from Queen’s University Belfast and The Centre for Security Technologies (CSIT) has received significant investment for its research in automated lip reading technology. Investment in the company has also been supported by QUBIS, the commercialisation arm of Queen’s, Invest Northern Ireland’s Access to Finance funds Techstart NI managed by Techstart Ventures
Automated lip-reading company Liopa gains Future Fund support for innovation Read More »
Clarendon Fund Managers Limited is a venture capital fund manager based in Belfast, authorised and regulated by the Financial Conduct Authority.
5th Floor
Craig Plaza
51 Fountain Street
Belfast, BT1 5EA
Co. Antrim
T: +44 (0)28 9032 6465
F: +44 (0)28 9032 6473
E: info@clarendon-fm.co.uk
Clarendon Fund Managers Limited is authorised and regulated by the Financial Conduct Authority
The content of the information and materials on the Website and any other information and materials provided by or though CFM in connection with Co-Fund NI and associated investment opportunities and Investee Companies, including any financial promotion as defined in Financial Services and Markets as Act 2000(“FSMA”) constituted thereby, has not been approved by an authorised person within the meaning of FSMA. Reliance on the information provided in relation to any specific Investee Company or otherwise, including any financial promotion constituted thereby, for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
© 2025 Clarendon Fund Managers. All rights reserved.